Marksans Pharma Q2 FY27 Earnings Call: Guides Rs. 4,000 Cr FY28 Revenue, Record Quarter Beats Margin Guidance

Marksans Pharma Ltd held its Q2 FY27 earnings call on November 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Record Quarter Beats Guidance, But Sequential PAT Slips

• Revenue of Rs.940 crore (+30.5% YoY, +11.8% QoQ) — a record quarter; total income rose 29.2% YoY to Rs.928 crore. Excluding the Clinic acquisition, underlying growth was ~25%.
• Record EBITDA of Rs.214 crore (+48.3% YoY) — margin expanded 274 bps to 22.8%, ahead of management's 20-21% guidance range (period unspecified).
• PAT of Rs.144 crore (+44.8% YoY; 15% net margin) — down sequentially from Rs.159 crore in Q1 FY 2026-2027 on higher D&A (amortisation of acquisition intangibles), lower other income and a 25.8% effective tax rate.
• H1 FY 2026-2027 revenue up 32.9% to Rs.1,781 crore — EBITDA up 74.7% to Rs.427 crore (24% margin); PAT up 92.5% to Rs.303 crore, aided by higher other income.
• Cash generation improved sharply — H1 operating cash flow of Rs.322 crore vs Rs.75 crore in H1 FY 2025-2026; cash conversion at 75.2% of EBITDA; free cash flow Rs.275 crore after Rs.46 crore capex.
• Balance sheet strengthened — net cash of Rs.1,095 crore at September-end; trailing 12-month ROCE improved to 24.7% (from 18.7%) and ROE to 18.6% (from 13.6%).

Europe and Australia Lead; US Steady; ROW Disrupted

• UK & Europe revenue of Rs.405 crore (+65% YoY; 43% of mix) — +49% excluding acquisitions; Clinic (Netherlands) contributed ~Rs.84 crore in H1 FY 2026-2027, with ABC and Marksans GmbH building the Germany platform.
• North America posted its highest-ever quarterly revenue of Rs.421 crore (+8.7% YoY; 44.8% of mix) — US price erosion in prescription products remains in single digits; management is "extremely optimistic" on the US market.
• Australia & New Zealand grew 64% YoY to ~Rs.101 crore (10.7% of mix) — driven by the branded prescription strategy under Nova, which markets 100% of the company's Australia sales.
• Rest of World at Rs.40 crore (1.5% of mix) — impacted by Middle East geopolitical disruptions and Red Sea logistics chaos affecting shipment timing; management characterised it as timing-related, not a change in underlying opportunity.
• US H1 softness attributed to seasonality and sentiment — management cited the cold-season (October-December) portfolio tilt plus consumer affordability pressure from inflation and crude, with medicines a lower priority than food and gas.

Gross Margin Peaking; API Prices and War the Swing Factors

• Gross margin at 58.5% (up 135 bps YoY, down from 59.1% in Q1) — management guided gross margin back to 55-56% for Q3 and Q4 FY 2026-2027 as the low-cost inventory benefit fades.
• Cost headwinds in Q2 — freight costs nearly doubled (~Rs.20 crore sequential rise in other expenses), employee costs up ~Rs.8 crore, and German operations incurred a couple of crores in startup costs.
• Elevated API prices (paracetamol, ibuprofen) seen cooling — management expects prices to ease "maybe in the next 30 days or so," contingent on crude prices falling; views elevated raw material costs as short-term and "not sustainable."
• War flagged as the key downside risk — management said if the war "goes from bad to worse," all projections go for a toss; margin upside beyond guidance is contingent on the war ending, with no formal guidance revision offered.
• Depreciation step-up of Rs.6-7 crore QoQ — CFO Jitendra Sharma attributed this to a Q2 FY 2026-2027 accounting change for intangibles (finite 10-year life) plus amortisation on ClinicU and ABC Now acquired intangibles; this level is the run-rate for Q3-Q4 FY 2026-2027.
• Lease liabilities rose Rs.120 crore in Q2 — driven by a new lease taken in the UK.

Rs.4,000 Crore in FY28; Long-Dated US, Australia and Europe Goals

• Rs.4,000 crore revenue guided for FY 2027-2028 — CMD Mark Saldanha said the company is trending close to Rs.1,000 crore per quarter (Q2 FY 2026-2027 run-rate) and can "very comfortably" hit the target next year; visibility also exists on a Rs.4,000 crore annualised mark for FY 2026-2027.
• Rs.5,000 crore within 3 years (by FY 2029-2030) — management is working towards this, and possibly doubling revenue to ~Rs.6,000 crore within 5 years (by FY 2031-2032).
• US order book targeted to rise from 225 to 300 crore within 3 years (by FY 2029-2030) — management expects 5-6 additional ANDA filings by March 2027 (FY 2026-2027) as part of a non-stop filing process.
• Australia expected to reach $100 million over the next 3 years (≈ by FY 2029-2030) — growth to be fueled by new launches, including nasal sprays currently outsourced but expected to be brought in-house (timeline unspecified).
• Europe target of Rs.1,000 crore top line in 5 years (≈ by FY 2031-2032) reaffirmed — management said the expanded European presence can create a meaningful growth channel beyond the UK over the next 3-5 years; Europe revenue streams are not factored into FY 2026-2027.
• UK growth called sustainable after a flat FY 2025-2026 — supported by the pipeline and visibility on upcoming approvals; revenue not expected to double overnight but to "grow significantly well."
• Volume-driven growth — CFO said a substantial part of H1 FY 2026-2027's 32.9% growth was volume-driven; OTC-RX mix steady at ~75% OTC / 25% RX; Q3 FY 2026-2027 is normally the stronger quarter, contingent on a strong winter.

M&A on Two Fronts; India Plant Acquisition Targeted in ~12 Months

• Two-front capital deployment — capex and M&A, with cash retained on the balance sheet to consummate acquisitions; management looks at a couple more M&As that may come across Europe (period unspecified), sized small to larger.
• India manufacturing acquisition in dialogue — management is in talks with two companies (nothing concrete yet) with a probable ~12-month timeline (i.e., during FY 2027-2028); CMD is evaluating assets across dosage forms, explicitly ruling out injectables, targeting forms where constraints are foreseen "maybe 2 years down the line" (~FY 2028-2029) — "there's always solid oral around it."
• Two-fold India capacity expansion toward 16 billion units per annum (period unspecified) — via new dosage blocks plus debottlenecking at the existing Teva plant infrastructure, and via plant acquisition.
• Oral solids capacity sufficient for the next 2-3 years — no current constraint, though management always wants additional capacity; ~98-99% of revenues come from own plants (US, UK, India) as of Q2 FY 2026-2027.
• More European deals hoped within 12 months (during FY 2027-2028) — management is exploring additional European M&As the Netherlands (Clinic) and Germany (ABC) platforms are country-specific and do not represent the whole of Europe.
• Access Healthcare (Dubai) "holding its own" — profitable and cash-generative despite the war, though revenue is extremely small relative to group turnover; management is working to increase its product pipeline ~10x (period unspecified). No Middle East acquisitions planned given the geopolitical scenario.
• Buyback remains an option — management has discussed it and will continue evaluating; a possibility if nothing else is happening on the capital deployment front (period unspecified).

FY27 Margin Guided Range-Bound; Dividend Unfinalised

• FY 2026-2027 EBITDA margin guided range-bound at 21-22% — in line with the Q2 level; the range-bound outlook reflects crude-oil-driven input cost inflation requiring replacement inventory at higher cost as low-cost stocks deplete.
• Q2 margin of 23% (per the analyst's framing) ran ahead of the ~21% full-year FY 2026-2027 guidance — asked if FY 2026-2027 margins could exceed ~21%, MD Mark Saldanha said it is "always a possibility" but contingent on the war ending, quipping one would have to "call the president and call off the war."
• ROW recovery conditional — management hopes to be back on track by end of FY 2026-2027; a quarterly run rate of Rs.20-25 crore is "doable" towards the exit of FY27 (FY 2026-2027), conditional on geopolitical easing; management declined to predict the war's duration, saying it has no crystal ball.
• Dividend policy for FY 2026-2027 not yet finalised — CMD said it still needs to be evaluated given multiple priorities; CFO Jitendra Sharma indicated it will "broadly" follow the historical practice of distributing one-third of free cash flow as dividend.
• H2 PAT seasonality not reaffirmed — on whether H2 FY 2026-2027 PAT will exceed H1 (the historical pattern), management did not explicitly reaffirm the trend; FY 2026-2027 PAT expected in line with expectations aside from taxation and depreciation provisions.
• No committed major capex cycle for FY 2027-2028 — management described its capex outlook as longer-term rather than immediate, with active dialogue on both adding a manufacturing block and acquiring a plant.